Literature DB >> 3049913

Prevention of experimental cerebral malaria by anticytokine antibodies. Interleukin 3 and granulocyte macrophage colony-stimulating factor are intermediates in increased tumor necrosis factor production and macrophage accumulation.

G E Grau1, V Kindler, P F Piguet, P H Lambert, P Vassalli.   

Abstract

IL-3 and granulocyte/macrophage colony stimulating factor (GM-CSF) are two cytokines released by activated T lymphocytes that stimulate the growth and differentiation of various hematopoietic cell lines, among which are macrophages. It has been shown that TNF/cachectin, another cytokine that is released mostly by activated macrophages, plays a central role in experimental cerebral malaria (CM), an acute and lethal neurological syndrome induced by Plasmodium berghei ANKA infection in CBA mice. Since CM requires functional CD4+ T lymphocytes to occur, we explored, by injecting rabbit antibodies to murine rIL-3 and/or GM-CSF, whether these cytokines are intermediates in the marked TNF release leading to CM. Treatment of infected mice with each antibody separately had no protective effect. In contrast, when both anti-rGM-CSF and anti-rIL-3 antibodies were injected together; (a) the occurrence of neurological syndrome was prevented in 90% of the cases; (b) the rise in serum TNF was prevented; and (c) macrophage accumulation in the spleen was significantly reduced. Murine CM appears to involve a cytokine cascade in which IL-3 and GM-CSF lead to the accumulation of TNF-releasing macrophages in vivo.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3049913      PMCID: PMC2189068          DOI: 10.1084/jem.168.4.1499

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  17 in total

1.  L3T4+ T lymphocytes play a major role in the pathogenesis of murine cerebral malaria.

Authors:  G E Grau; P F Piguet; H D Engers; J A Louis; P Vassalli; P H Lambert
Journal:  J Immunol       Date:  1986-10-01       Impact factor: 5.422

2.  Monoclonal antibody MB19 detects genetic polymorphism in human apolipoprotein B.

Authors:  S G Young; S J Bertics; L K Curtiss; D C Casal; J L Witztum
Journal:  Proc Natl Acad Sci U S A       Date:  1986-02       Impact factor: 11.205

3.  Human cerebral malaria: a pathological study.

Authors:  M M Oo; M Aikawa; T Than; T M Aye; P T Myint; I Igarashi; W C Schoene
Journal:  J Neuropathol Exp Neurol       Date:  1987-03       Impact factor: 3.685

4.  Tumor necrosis factor (cachectin) as an essential mediator in murine cerebral malaria.

Authors:  G E Grau; L F Fajardo; P F Piguet; B Allet; P H Lambert; P Vassalli
Journal:  Science       Date:  1987-09-04       Impact factor: 47.728

5.  Hemopoietic responses in mice injected with purified recombinant murine GM-CSF.

Authors:  D Metcalf; C G Begley; D J Williamson; E C Nice; J De Lamarter; J J Mermod; D Thatcher; A Schmidt
Journal:  Exp Hematol       Date:  1987-01       Impact factor: 3.084

6.  Tumor necrosis factor type alpha stimulates human endothelial cells to produce granulocyte/macrophage colony-stimulating factor.

Authors:  V C Broudy; K Kaushansky; G M Segal; J M Harlan; J W Adamson
Journal:  Proc Natl Acad Sci U S A       Date:  1986-10       Impact factor: 11.205

7.  Macrophage plasma membrane and secretory properties in murine malaria. Effects of Plasmodium yoelii blood-stage infection on macrophages in liver, spleen, and blood.

Authors:  S H Lee; P Crocker; S Gordon
Journal:  J Exp Med       Date:  1986-01-01       Impact factor: 14.307

8.  Gamma interferon enhances macrophage transcription of the tumor necrosis factor/cachectin, interleukin 1, and urokinase genes, which are controlled by short-lived repressors.

Authors:  M A Collart; D Belin; J D Vassalli; S de Kossodo; P Vassalli
Journal:  J Exp Med       Date:  1986-12-01       Impact factor: 14.307

9.  Recombinant granulocyte/macrophage colony-stimulating factor activates macrophages to inhibit Trypanosoma cruzi and release hydrogen peroxide. Comparison with interferon gamma.

Authors:  S G Reed; C F Nathan; D L Pihl; P Rodricks; K Shanebeck; P J Conlon; K H Grabstein
Journal:  J Exp Med       Date:  1987-12-01       Impact factor: 14.307

10.  Additive effects of interleukin 1 and tumour necrosis factor-alpha on the accumulation of the three granulocyte and macrophage colony-stimulating factor mRNAs in human endothelial cells.

Authors:  W K Seelentag; J J Mermod; R Montesano; P Vassalli
Journal:  EMBO J       Date:  1987-08       Impact factor: 11.598

View more
  26 in total

1.  Early microvascular changes in murine cerebral malaria detected in retinal wholemounts.

Authors:  T Chang-Ling; A L Neill; N H Hunt
Journal:  Am J Pathol       Date:  1992-05       Impact factor: 4.307

Review 2.  Tumor necrosis factor and immunopathology.

Authors:  P F Piguet; G E Grau; P Vassalli
Journal:  Immunol Res       Date:  1991       Impact factor: 2.829

3.  Distinct clinical and immunologic profiles in severe malarial anemia and cerebral malaria in Zambia.

Authors:  Philip E Thuma; Janneke van Dijk; Rick Bucala; Zufan Debebe; Sergei Nekhai; Thea Kuddo; Mehdi Nouraie; Günter Weiss; Victor R Gordeuk
Journal:  J Infect Dis       Date:  2011-01-15       Impact factor: 5.226

Review 4.  Host-parasite interaction and morbidity in malaria endemic areas.

Authors:  K Marsh; R W Snow
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1997-09-29       Impact factor: 6.237

Review 5.  Oxidative stress in malaria; implications for prevention and therapy.

Authors:  N S Postma; E C Mommers; W M Eling; J Zuidema
Journal:  Pharm World Sci       Date:  1996-08

6.  Cloned lines of Plasmodium berghei ANKA differ in their abilities to induce experimental cerebral malaria.

Authors:  V Amani; M I Boubou; S Pied; M Marussig; D Walliker; D Mazier; L Rénia
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

7.  Anti-tumor necrosis factor modulates anti-CD3-triggered T cell cytokine gene expression in vivo.

Authors:  C Ferran; F Dautry; S Mérite; K Sheehan; R Schreiber; G Grau; J F Bach; L Chatenoud
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

8.  Tumour necrosis factor-dependent parasite-killing effects during paroxysms in non-immune Plasmodium vivax malaria patients.

Authors:  N D Karunaweera; R Carter; G E Grau; D Kwiatkowski; G Del Giudice; K N Mendis
Journal:  Clin Exp Immunol       Date:  1992-06       Impact factor: 4.330

9.  Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor.

Authors:  P F Piguet; G E Grau; C Vesin; H Loetscher; R Gentz; W Lesslauer
Journal:  Immunology       Date:  1992-12       Impact factor: 7.397

10.  Parasite virulence factors during falciparum malaria: rosetting, cytoadherence, and modulation of cytoadherence by cytokines.

Authors:  P Ringwald; F Peyron; J P Lepers; P Rabarison; C Rakotomalala; M Razanamparany; M Rabodonirina; J Roux; J Le Bras
Journal:  Infect Immun       Date:  1993-12       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.